Omeros Corporation (OMER)

$3.35

+0.06

(+1.82%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Omeros Corporation

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.0% return, outperforming this stock by 109.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.7% return, outperforming this stock by 316.4%

Performance

  • $3.30
    $3.37
    $3.35
    downward going graph

    1.64%

    Downside

    Day's Volatility :2.23%

    Upside

    0.59%

    downward going graph
  • $0.92
    $7.80
    $3.35
    downward going graph

    72.54%

    Downside

    52 Weeks Volatility :88.21%

    Upside

    57.05%

    downward going graph

Returns

PeriodOmeros CorporationSector (Health Care)Index (Russel 2000)
3 Months
-26.37%
-1.8%
0.0%
6 Months
66.67%
10.1%
0.0%
1 Year
-42.04%
13.2%
0.0%
3 Years
-77.65%
17.0%
-21.4%

Highlights

Market Capitalization
198.2M
Book Value
- $1.23
Earnings Per Share (EPS)
-2.96
PEG Ratio
-0.17
Wall Street Target Price
43.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-21.03%
Return On Equity TTM
-576.33%
Revenue TTM
-30.0M
Revenue Per Share TTM
-0.48
Quarterly Revenue Growth YOY
14.899999999999999%
Gross Profit TTM
-71.4M
EBITDA
-166.9M
Diluted Eps TTM
-2.96
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.44
EPS Estimate Next Year
-1.98
EPS Estimate Current Quarter
-0.58
EPS Estimate Next Quarter
-0.56

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Omeros Corporation(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
1
7
Hold
2
4
3
Sell
00
4
1

Analyst Forecast

What analysts predicted

Upside of 1183.58%

Current $3.35
Target $43.00

Technicals Summary

Sell

Neutral

Buy

Omeros Corporation is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Omeros Corporation
Omeros Corporation
6.35%
66.67%
-42.04%
-77.65%
-81.03%
Moderna, Inc.
Moderna, Inc.
54.31%
114.37%
31.98%
-5.11%
673.49%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
11.53%
23.42%
35.86%
98.13%
219.88%
Novo Nordisk A/s
Novo Nordisk A/s
7.24%
30.97%
66.95%
238.66%
467.54%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
14.96%
30.49%
38.47%
120.96%
164.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Omeros Corporation
Omeros Corporation
1.43
NA
-0.17
-2.44
-5.76
-0.21
NA
-1.23
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.6
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.99
28.99
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.23
29.23
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Omeros Corporation
Omeros Corporation
Buy
$198.2M
-81.03%
1.43
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$63.9B
673.49%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
219.88%
28.99
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$605.7B
467.54%
46.75
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.3B
164.5%
29.23
39.46%

Institutional Holdings

  • Ingalls & Snyder LLC

    7.85%
  • BlackRock Inc

    7.39%
  • Vanguard Group Inc

    5.47%
  • Stifel Financial Corp

    3.26%
  • D. E. Shaw & Co LP

    2.35%
  • Geode Capital Management, LLC

    2.31%

Company Information

omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Organization
Omeros Corporation
Employees
198
CEO
Dr. Gregory A. Demopulos M.D.
Industry
Health Technology

FAQs